367 related articles for article (PubMed ID: 28341962)
1. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z; Asaduzzaman M; Kumar U; Masrour N; Jugov R; Coombes RC; Shousha S; Hu Y; Lam EW; Yagüe E
Biochem Pharmacol; 2019 May; 163():391-403. PubMed ID: 30862505
[TBL] [Abstract][Full Text] [Related]
3. MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.
Hu Y; Li K; Asaduzzaman M; Cuella R; Shi H; Raguz S; Coombes RC; Zhou Y; Yagüe E
Oncol Rep; 2016 Feb; 35(2):1170-8. PubMed ID: 26573761
[TBL] [Abstract][Full Text] [Related]
4. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
5. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions.
Sasaki N; Ishiwata T; Hasegawa F; Michishita M; Kawai H; Matsuda Y; Arai T; Ishikawa N; Aida J; Takubo K; Toyoda M
Cancer Sci; 2018 Apr; 109(4):1135-1146. PubMed ID: 29444383
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells.
Jang JY; Kim MK; Jeon YK; Joung YK; Park KD; Kim CW
Exp Mol Med; 2012 Apr; 44(4):251-9. PubMed ID: 22198296
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles.
Das S; Mukherjee P; Chatterjee R; Jamal Z; Chatterji U
Mol Cancer Ther; 2019 Mar; 18(3):680-692. PubMed ID: 30587555
[TBL] [Abstract][Full Text] [Related]
8. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
9. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
Yakisich JS; Venkatadri R; Azad N; Iyer AKV
J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
[TBL] [Abstract][Full Text] [Related]
11. The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300.
Zhou Y; Hu Y; Yang M; Jat P; Li K; Lombardo Y; Xiong D; Coombes RC; Raguz S; Yagüe E
Cell Death Differ; 2014 Mar; 21(3):462-74. PubMed ID: 24270410
[TBL] [Abstract][Full Text] [Related]
12. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
13. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
14. An integrated analysis to predict micro-RNAs targeting both stemness and metastasis in breast cancer stem cells.
Rahimi M; Sharifi-Zarchi A; Firouzi J; Azimi M; Zarghami N; Alizadeh E; Ebrahimi M
J Cell Mol Med; 2019 Apr; 23(4):2442-2456. PubMed ID: 30710426
[TBL] [Abstract][Full Text] [Related]
15. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
16. ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Leccia F; Del Vecchio L; Mariotti E; Di Noto R; Morel AP; Puisieux A; Salvatore F; Ansieau S
Mol Cancer; 2014 Sep; 13():213. PubMed ID: 25216750
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
Shi R; Wang C; Fu N; Liu L; Zhu D; Wei Z; Zhang H; Xing J; Wang Y
Oncol Rep; 2019 May; 41(5):3015-3026. PubMed ID: 30896886
[TBL] [Abstract][Full Text] [Related]
18. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
19. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
20. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
